Cullen/Frost Bankers’s Amedisys AMED Stock Holding History

Cullen/Frost Bankers’s Portfolio AMED Stock Details AMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-38	Closed	-$3.52K	–	1303
2025 Q1	$3.52K	Buy	+38	New	+$3.5K	﹤0.01%	1095
2023 Q3	–	Sell	-309	Closed	-$28.3K	–	1153
2023 Q2	$28.3K	Sell	309 -23	-7%	-$1.89K	﹤0.01%	817
2023 Q1	$24.4K	Hold	332	–	–	﹤0.01%	832
2022 Q4	$27.7K	Hold	332	–	–	﹤0.01%	790
2022 Q3	$32K	Hold	332	–	–	﹤0.01%	775
2022 Q2	$35K	Sell	332 -22	-6%	-$2.81K	﹤0.01%	755
2022 Q1	$61K	Hold	354	–	–	﹤0.01%	705
2021 Q4	$57K	Buy	354 +113	+47%	+$18.2K	﹤0.01%	728
2021 Q3	$36K	Hold	241	–	–	﹤0.01%	839
2021 Q2	$59K	Buy	241 +37	+18%	+$9.71K	﹤0.01%	747
2021 Q1	$54K	Hold	204	–	–	﹤0.01%	710
2020 Q4	$60K	Hold	204	–	–	﹤0.01%	674
2020 Q3	$48K	Hold	204	–	–	﹤0.01%	678
2020 Q2	$41K	Buy	+204	New	+$38K	﹤0.01%	687

Other funds holding AMED

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TAL

TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Cullen/Frost Bankers's AMED Position: Q2 2025 in Review

Cullen/Frost Bankers sold out of Amedisys (AMED) in Q2 2025, closing a stake of 38 shares — an estimated $3.52K sold.

Cullen/Frost Bankers first reported a position in AMED in Q2 2020 and held it in 14 quarters. The position peaked at $61K in Q1 2022. 319 funds tracked by Wall St. Rank hold AMED as of Q2 2025.

Cullen/Frost Bankers reported no remaining Amedisys position as of Q2 2025 after selling out during the quarter.
Cullen/Frost Bankers sold 38 Amedisys shares in Q2 2025, an estimated $3.52K.
Cullen/Frost Bankers first reported a position in Amedisys in Q2 2020 and held it in 14 quarters.
Cullen/Frost Bankers's Amedisys position peaked at $61K in Q1 2022.
319 funds tracked by Wall St. Rank held Amedisys as of Q2 2025.

Based on Cullen/Frost Bankers's 13F filing for Q2 2025, filed 30 Jul 2025.